Study of Circulating Tumor DNA and Exosomes in Digestive, Gynecologic, and Breast Cancers Using Blood Tests to Improve Cancer Diagnosis and Treatment Monitoring

What this Trial Is About

Researchers are investigating the role of circulating tumor DNA ctDNA and exosomes in digestive, gynecological, and breast cancers. These markers can be detected through simple blood tests and provide information about tumor genetics, treatment response, and disease progression. The study aims to assess the diagnostic, prognostic, and predictive value of ctDNA and exosomes in a large prospective group of patients, building on recent advances in molecular biology and sensitive techniques like Next Generation Sequencing NGS. The study involves collecting blood samples at various times during patients cancer treatment, including at the start, during therapy, at progression or relapse, and during treatment breaks. The focus is on analyzing ctDNA for mutations and genetic alterations that may influence therapy, as well as studying the composition of exosomes. Only one study group is involved, with patients undergoing blood draws for these analyses. Participants will have their blood collected for ctDNA and exosome analysis and will be monitored over an average of 12 months. Researchers will evaluate outcomes such as mortality related to ctDNA levels, diagnostic value of ctDNA and exosomes, their prognostic impact, predictive value for treatment response or resistance, and detection of molecular changes. This study is observational with no masking, and participants health and treatment progress will be tracked throughout.

Interest of Circulating Tumor DNA in Digestive and Gynecologic/Breast Cancer